CFDA’s Approval Of Gilupi’s CellCollector for In-Vivo CTC Isolation Signifies The Importance of Partnership Between International Medical Device Manufacturers and Chinese Local Firms

CFDA Updates:CFDA Has Issued 2 Notice on On-site Consultation
July 27, 2017
China Deepening Its Medical Device Registration and Regulation Reform
August 7, 2017

CFDA’s Approval Of Gilupi’s CellCollector for In-Vivo CTC Isolation Signifies The Importance of Partnership Between International Medical Device Manufacturers and Chinese Local Firms

To enter the Chinese market, partnership forged between international medical device manufacturers and local Chinese firms is on the rise. In such partnership, the medical device companies are working with local Chinese firms to accelerate CFDA regulatory process, China market commercialization and sometimes also to obtain needed growth capital and local manufacturing and distribution.

 

As a recent example of this type of partnership, CFDA has approved CellCollector® manufactured by Gilupi, a medical device for in vivo CTC isolation. Gilupi, the Potsdam, Germany-based company now gains access to one of the most significant geographical markets worldwide. This significant market development success by Gilupi was reached in partnership with with its strategic partner, Hebei Viroad Biotechnology (Viroad). Besides its role as a strategic partner, Viroad is also the largest investor and shareholder of Gilupi.

China Med Device, LLC, specializing in providing turn-key solutions for medical device medtech companies entry into China, brings you up-to-date information on CFDA and China medical device market moves. CMD provides on-demand services covering Chinese market assessment, CFDA regulatory and approval process, commercialization, device manufacturing and distribution.  If you have any feedback, please email us at info@ChinaMedDevice.com or visit us at www.ChinaMedDevice.com.